Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) rose 3.1% on Wednesday . The company traded as high as $47.49 and last traded at $47.13, with a volume of 206,604 shares traded. The stock had previously closed at $45.73.

A number of research analysts recently commented on EGRX shares. Mizuho restated a “buy” rating and issued a $71.00 price target on shares of Eagle Pharmaceuticals in a research report on Tuesday, March 29th. Piper Jaffray Cos. restated an “overweight” rating and issued a $98.00 price target on shares of Eagle Pharmaceuticals in a research report on Thursday, April 7th. Royal Bank Of Canada decreased their price target on Eagle Pharmaceuticals from $94.00 to $78.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 10th. Finally, Zacks Investment Research upgraded Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $88.94.

The firm’s market cap is $733.95 million. The stock’s 50-day moving average price is $43.39 and its 200-day moving average price is $50.16.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by $0.52. The business earned $29.60 million during the quarter, compared to analysts’ expectations of $29.07 million. During the same period in the previous year, the business earned $1.31 EPS. Eagle Pharmaceuticals’s revenue for the quarter was down 18.5% on a year-over-year basis. On average, equities analysts forecast that Eagle Pharmaceuticals Inc. will post $3.32 EPS for the current year.

In other news, major shareholder Proquest Management Llc sold 17,980 shares of the company’s stock in a transaction on Friday, May 13th. The stock was sold at an average price of $40.72, for a total transaction of $732,145.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Other hedge funds and institutional investors have recently modified their holdings of the company. Century Capital Management LLC boosted its position in shares of Eagle Pharmaceuticals by 34.4% in the fourth quarter. Century Capital Management LLC now owns 66,209 shares of the specialty pharmaceutical company’s stock worth $5,871,000 after buying an additional 16,942 shares in the last quarter. Turner Investments L.P. bought a new stake in shares of Eagle Pharmaceuticals during the fourth quarter worth about $2,350,000. Bank of Montreal Can boosted its stake in shares of Eagle Pharmaceuticals by 62.3% in the fourth quarter. Bank of Montreal Can now owns 119,902 shares of the specialty pharmaceutical company’s stock worth $10,632,000 after buying an additional 46,020 shares during the period. OppenheimerFunds Inc. bought a new stake in shares of Eagle Pharmaceuticals during the fourth quarter worth about $6,104,000. Finally, ProShare Advisors LLC bought a new stake in shares of Eagle Pharmaceuticals during the fourth quarter worth about $1,222,000.

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care, orphan diseases and oncology areas. Its commercial products include Argatroban Injection, Ryanodex (dantrolene sodium) for injectable suspension, Diclofenac sodium misoprostol and Docetaxel Injection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.